Biotech giant Regeneron Pharmaceuticals has acquired 23andMe for $256 million, following the DNA testing company’s bankruptcy earlier this year.
The deal includes 23andMe’s Total Health and Research Services business and its massive biobank of anonymized customer data and genetic samples.
Once valued at $6 billion after its 2021 IPO, 23andMe filed for Chapter 11 bankruptcy in March 2025 amid mounting financial losses. The acquisition, still subject to approval by the U.S. Bankruptcy Court, positions Regeneron to expand its large-scale genetics research aimed at developing new drugs and treatments.
23andMe claims to have collected DNA data from over 15 million customers through its popular at-home testing kits. The company asserts that all customer data is anonymized, and genetic samples are destroyed when users delete their accounts. However, questions remain about how much information will now be accessible to Regeneron.
“We are pleased to have reached a transaction that maximizes the value of the business and enables the mission of 23andMe to live on,” said Mark Jensen, Chair of 23andMe. Regeneron has also pledged to retain all current employees of the acquired business units.
The move highlights the growing intersection of consumer genetics and pharmaceutical research, with privacy advocates watching closely to ensure users’ data rights are respected in the transition.
If this article helped you, please consider supporting our work. Every small contribution keeps Abijita.com independent and running.
